We know ADC and XDC. From synthesis to signal.

We performs precise, scalable conjugation of antibodies, proteins, peptides and polymer systems with highly potent payloads under GMP conditions. The platform supports single and dual-payload constructs, including cytotoxic payloads and oligonucleotide payloads (AOCs), with bioconjugation carried out in Ardena’s precision-medicine cleanroom.

Process design focuses on the parameters that matter most for conjugate quality: drug-to-antibody ratio (DAR), conjugation heterogeneity, yield and process robustness, with site-specific conjugation approaches available where program design requires it.

Our bioanalytical service covers quantification of all ADC molecular entities — including total antibody, conjugated payload and free payload — together with immunogenicity and associated biomarker readouts. Ardena’s analytical labs are fully GLP compliant and support programs through preclinical and clinical phases.

ADCs are one segment of a rapidly evolving conjugate field. Building on our work in linker chemistry, bioconjugation chemistry and bioanalysis, we support developers advancing next-generation XDC platforms.

Our experience extends to emerging conjugate formats including oligonucleotide conjugates, polymer-drug conjugates, nanoparticle-drug conjugates and Immune Stimulating Antibody Conjugates (ISACs). By combining drug linker chemistry, nanomedicine formulation and bioconjugation expertise, we help bring next-generation targeted therapies forward.